Advertisement
YOU ARE HERE: LAT HomeCollectionsVical Inc
IN THE NEWS

Vical Inc

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
October 14, 2003 | From Bloomberg News
Vical Inc., a San Diego biotechnology company developing infectious-disease treatments, said it signed an agreement with the U.S. to manufacture an experimental SARS vaccine. Terms were not disclosed. The manufacturing order for a severe acute respiratory disease preventive medicine came from the National Institutes of Health and was in addition to one announced in July for West Nile virus and another in 2002 for the Ebola virus. Vical shares rose 38 cents to $6.20 on Nasdaq.
Advertisement
BUSINESS
October 14, 2003 | From Bloomberg News
Vical Inc., a San Diego biotechnology company developing infectious-disease treatments, said it signed an agreement with the U.S. to manufacture an experimental SARS vaccine. Terms were not disclosed. The manufacturing order for a severe acute respiratory disease preventive medicine came from the National Institutes of Health and was in addition to one announced in July for West Nile virus and another in 2002 for the Ebola virus. Vical shares rose 38 cents to $6.20 on Nasdaq.
BUSINESS
July 31, 1999 | Bloomberg News
Vical Inc. shares soared on news that Merck & Co. will soon begin human tests of an AIDS vaccine that uses DNA technology developed by Vical. San Diego-based Vical has agreements with Merck for the use of its so-called naked DNA technology in experimental vaccines for seven diseases, including HIV. Vical's method allows for direct injection of genetic material into muscle tissue, where more traditional methods use viruses to carry DNA into cells.
BUSINESS
July 31, 1999 | Bloomberg News
Vical Inc. shares soared on news that Merck & Co. will soon begin human tests of an AIDS vaccine that uses DNA technology developed by Vical. San Diego-based Vical has agreements with Merck for the use of its so-called naked DNA technology in experimental vaccines for seven diseases, including HIV. Vical's method allows for direct injection of genetic material into muscle tissue, where more traditional methods use viruses to carry DNA into cells.
BUSINESS
June 2, 1998 | From Bloomberg News
Vical Inc. shares rose 10% after the company reported strong results from a 20-patient trial of its potential prostate cancer drug called Leuvectin. Shares in the San Diego-based company rose $1.63 to close at $17.88 on Nasdaq in trading of 575,700 shares, more than six times the average daily volume for the stock in the past six months. "I think this is a very significant finding," said Albert Rauch, an analyst at Everen Securities.
BUSINESS
March 11, 2003 | From Associated Press
A San Diego biotechnology company said Monday that it hoped to begin human testing of its experimental anthrax vaccine by year's end. Vical Inc. is among several companies racing to create a better vaccine than the one now available and manufactured by BioPort Inc. of Lansing, Mich. Vical presented data Monday that showed its novel DNA vaccine protected rabbits that inhaled anthrax, with little side effect.
BUSINESS
April 26, 1994 | JONATHAN WEBER, TIMES STAFF WRITER
A raging bull market and an economic recovery made 1993 a record year for initial public stock offerings, and dozens of California companies rejoiced as their share prices soared following their Wall Street debut. Companies from a broad range of industries shared in the prosperity, though technology firms led the pack, as in previous years.
BUSINESS
June 2, 1998 | From Bloomberg News
Vical Inc. shares rose 10% after the company reported strong results from a 20-patient trial of its potential prostate cancer drug called Leuvectin. Shares in the San Diego-based company rose $1.63 to close at $17.88 on Nasdaq in trading of 575,700 shares, more than six times the average daily volume for the stock in the past six months. "I think this is a very significant finding," said Albert Rauch, an analyst at Everen Securities.
BUSINESS
December 5, 2005 | From Associated Press
Two years ago, as fears of a SARS pandemic spread, a San Diego biotech company aided by federal dollars speeded a promising vaccine out of the lab and into human testing. But when Vical Inc. and the government wrap up the 15-person test next year, the drug is expected to end up on the shelf because the dreaded global epidemic never panned out. Bird flu has now passed SARS as the No. 1 feared global death threat.
CALIFORNIA | LOCAL
December 2, 1992 | GREG HERNANDEZ
A metal company has agreed to pay between $50,000 and $75,000 to clean up contaminated Buckeye Creek, the Orange County district attorney's office announced Tuesday. Vi-Cal Metals Inc., at 1635 N. Case St., will pay to remove metal-cutting oils, which reportedly leaked from their plant into a storm drain that leads to the nearby creek, said Deputy Dist. Atty. Michelle Lyman. "They basically kept a sloppy shop as opposed to the intentional dumping of hazardous waste," Lyman said.
Los Angeles Times Articles
|